Cambium Bio Limited (ASX:CMB)

Market Cap	13.09M +213.5%
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	22.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	15,783
Open	0.5700
Previous Close	0.5700
Day's Range	0.5700 - 0.5700
52-Week Range	0.1900 - 0.6400
Beta	-0.24
RSI	61.33
Earnings Date	n/a

About Cambium Bio

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CMB